Overview

Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials

Status:
Active, not recruiting

Trial end date:
2022-05-01

Target enrollment:
0

Participant gender:
All

Summary

To allow continuation of axitinib (AG 013736) treatment to patients experiencing clinical benefit in a closing axitinib trial

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Pfizer

Treatments:

Axitinib
Crizotinib

Criteria

Inclusion Criteria:

- Patients who were assigned to an axitinib (AG-013736) containing treatment arm in a
previous clinical trial

- Patients who were receiving axitinib (AG-013736) tablets at the time their previous
trial ended

- Patients who have stable (SD) or responding disease (PR or CR) documented by the
appropriate radiological, clinical, or laboratory assessments within 12 weeks before
enrollment (Note: response criteria from the previous axitinib (AG-013736) protocol
should be used to determine stable or responding disease).

- Patients who have progressive disease (PD) but have experienced "clinical benefit" as
defined in the study protocol

Exclusion Criteria:

- Patients may not participate in this trial if the conditions for continuing treatment
in the previous axitinib (AG-013736) protocol are not met